The Pharmaceutical Journal
Vol 274 No 7340 p289
12 March 2005

This article
Reprint   Photocopy

  Acrobat Reader

News summary

Generics company executives expected to face fraud charges

Executives of various generics companies are likely to face criminal charges following an extended investigation by the Serious Fraud Office. An SFO spokesman said that those under investigation are likely to be interviewed under caution in the next few months. Decisions will then be made on who could or should be charged and in relation to what offences.

The SFO investigation began in 2002 when it raided the offices of six suppliers of generic medicines (PJ, 13 April 2002, p487). The investigation has since been widened to include other companies.